Objective: We aimed to summarize the clinicopathological characteristics and prognostic features of various molecular subtypes of diffuse gliomas (DGs) in the Chinese population.Methods: In total, 1,418 patients diagnosed with DG between 2011 and 2017 were classified into 5 molecular subtypes according to the 2016 WHO classification of central nervous system tumors. The IDH mutation status was determined by immunohistochemistry and/or DNA sequencing, and 1p/19q codeletion was detected with fluorescence in situ hybridization. The median clinical follow-up time was 1,076 days. T-tests and chi-square tests were used to compare clinicopathological characteristics. Kaplan?Meier and Cox regression methods were used to evaluate prognostic factors. Results: Our cohort included 15.5％ lower-grade gliomas, IDH-mutant and 1p/19q-codeleted (LGG-IDHm-1p/19q); 18.1％ lower-grade gliomas, IDH-mutant (LGG-IDHm); 13.1％ lower-grade gliomas, IDH-wildtype (LGG-IDHwt); 36.1％ glioblastoma, IDH-wildtype (GBM-IDHwt); and 17.2％ glioblastoma, IDH-mutant (GBM-IDHm). Approximately 63.3％ of the enrolled primary gliomas, and the median overall survival times for LGG-IDHm, LGG-IDHwt, GBM-IDHwt, and GBM-IDHm subtypes were 75.97, 34.47, 11.57, and 15.17 months, respectively. The 5-year survival rate of LGG-IDHm-1p/19q was 76.54％. We observed a significant association between high resection rate and favorable survival outcomes across all subtypes of primary tumors. We also observed a significant role of chemotherapy in prolonging overall survival for GBM-IDHwt and GBM-IDHm, and in prolonging post-relapse survival for the 2 recurrent GBM subtypes. Conclusions: By controlling for molecular subtypes, we found that resection rate and chemotherapy were 2 prognostic factors associated with survival outcomes in a Chinese cohort with DG.

Kenan Zhang;Xing Liu;Guanzhang Li;Xin Chang;Shouwei Li;Jing Chen;Zheng Zhao;Jiguang Wang;Tao Jiang;Ruichao Chai

Department of Molecular Pathology,Beijing Neurosurgical Institute,Capital Medical University,Beijing 100070,China;Department of Neuropathology,Beijing Neurosurgical Institute,Capital Medical University,Beijing 100070,China;Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China;Department of Neurosurgery,Beijing Sanbo Brain Hospital,Capital Medical University,Beijing 100093,China;Division of Life Science and State Key Laboratory of Molecular Neuroscience,Department of Chemical and Biological Engineering,The Hong Kong University of Science and Technology,Clear Water Bay,Kowloon,Hong Kong SAR 999077,China;Hong Kong Center for Neurodegenerative Diseases,Hong Kong Science Park,Hong Kong SAR 999077,China;HKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute,Futian,Shenzhen 518057,China

癌症生物学与医学（英文版）

[1]Kenan Zhang;Xing Liu;Guanzhang Li;Xin Chang;Shouwei Li;Jing Chen;Zheng Zhao;Jiguang Wang;Tao Jiang;Ruichao Chai-.Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA)[J].癌症生物学与医学（英文版）,2022(10):1460-1476

codeletion,codeleted,IDHm,IDHwt

Clinical,management,survival,outcomes,patients,different,molecular,subtypes,diffuse,gliomas,China,multicenter,retrospective,study,from,CGGA,Objective,We,aimed,summarize,clinicopathological,characteristics,prognostic,features,various,DGs,Chinese,population,Methods,In,total,diagnosed,between,were,classified,into,according,WHO,classification,central,nervous,system,tumors,mutation,status,was,determined,by,immunohistochemistry,sequencing,1p,19q,detected,fluorescence,situ,hybridization,median,clinical,follow,up,days,tests,chi,square,used,compare,Kaplan,Meier,Cox,regression,methods,evaluate,factors,Results,Our,cohort,included,lower,grade,mutant,LGG,wildtype,glioblastoma,GBM,Approximately,enrolled,primary,overall,times,months,respectively,year,rate,observed,significant,association,high,resection,favorable,across,also,role,chemotherapy,prolonging,post,relapse,recurrent,Conclusions,By,controlling,found,that,associated

0.423799